Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Afuresertib + LAE001 + Prednisone|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Afuresertib||GSK2110183||Akt Inhibitor (Pan) 18 AKT Inhibitor (Pan) - ATP competitive 7||Afuresertib (GSK2110183) is a pan-AKT, ATP-competitive inhibitor, which may result in inhibition of the PI3K/AKT signaling pathway and tumor cell proliferation, and induction of tumor cell apoptosis (PMID: 25075128).|
|LAE001||Limited information is currently available on LAE001, a putative reversible inhibitor of CYP17A1 and CYP11B2 (Mar 2020).|
|Prednisone||Adasone||Dehydrocortisone||Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04060394||Phase Ib/II||Afuresertib + LAE001 + Prednisone Afuresertib||Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC||Recruiting|